Biotech
Samsung Bioepis
2
Articles
Deal Party
Top Role
Apr 7, 2026
First Mention
Apr 11, 2026
Last Mention
2.22
Relevance Score
Coverage Timeline
April 2026
Biosimilars Beyond Humira: New Pressures and Unwritten Rules for Stelara, Keytruda, and Eylea in 2026
Pipeline
Deal Party
Apr 11, 2026
Amgen’s ABP 654 and Samsung Bioepis’s SB17 won’t launch until late 2025 at the earliest.
Novartis Spins Off Sandoz: What the $10B Pure-Play Means for Biosimilar Strategies and Drug Pricing 2025-2026
Deals
Competitor
Apr 7, 2026
Biocon and Samsung Bioepis are investing aggressively stateside.